Feasibility of telephone and computerized cognitive testing as a secondary outcome in an acute stroke clinical trial: A mixed methods sub-study of the AcT Trial

Abstract

Introduction:

Post-stroke cognitive impairment is associated with impaired quality of life. Remote testing provides a potential avenue to measure cognitive outcomes efficiently.

Patients and Methods:

Prospective cognitive outcomes were collected at 90–180 days using both telephone MoCA (T-MoCA; range 0–22; <17 impairment) and Creyos, a computerized cognitive battery. Key variables associated with completion were assessed using logistic regressions. Mixed methods brief structured interviews and exit survey were performed to explore barriers to completing computer testing.

Results:

Of 791 potentially eligible patients (mean age 70 ± 14 years), there was low feasibility of remote cognitive testing, with only 401 (51%) completing the T-MoCA, and 242 (31%) completing Creyos. Our regression models show that age (OR_T-MoCA: 0.95 (95% Confidence Interval (CI): 0.94–0.97); OR_Creyos: 0.95 (95% CI: 0.94–0.96)), functional impairment (mRS 2–5; OR_T-MoCA: 0.55 (95% CI: 0.37–0.81); OR_Creyos: 0.66 (95% CI: 0.44–0.98)), quality of life (EQ-VAS; OR_T-MoCA: 1.02 (95% CI: 1.01–1.03); OR_Creyos: OR:1.02 (95% CI: 1.01–1.03)) and length of hospital stay (OR_T-MoCA: 0.98 (95% CI: 0.96–0.99); OR_Creyos: 0.97 (95% CI: 0.94–0.99)) predicted both telephone and computer cognitive test completion; computer literacy predicted computer test completion (OR_Creyos: 1.12 (95% CI: 1.04–1.21)). In interviews, a preference for accessibility of computerized testing was reported.

Discussion:

Remote cognitive testing has limited feasibility as a secondary outcome in large acute stroke trials. Patients who are older, with worse quality of life, or severe functional impairment post-stroke are less likely to complete remote cognitive outcomes.

Conclusion:

Innovative approaches to post-stroke cognitive outcomes in acute stroke trials are needed.

Data Access

Data available upon request.

Graphical abstract

Keywords

Stroke clinical trials cognitive endpoint telephone assessment computerized assessment

Introduction

Cognitive deficits are common after stroke, with up to 80% of patients having some degree of cognitive impairment (CI).¹ Cognitive impairment is often underdiagnosed and under-treated.² Patients with poorer cognition have greater functional impairment and are at a higher risk for both mortality and stroke recurrence.³ Despite cognitive impairment being present in many stroke survivors, the primary end points of most randomized controlled trials (RCT’s) in stroke focus on global measures of physical function and rehabilitation,⁴ which do not reflect cognition well.⁵

Though many guidelines have recommended the use of cognitive assessments after stroke both clinically and in stroke clinical trials,^6–8 they remain infrequently used in trials, with substantial heterogeneity in approaches.^9,10 Even when embedded in clinical trials, in-person cognitive testing has significant limitations. The Montreal Cognitive Assessment (MoCA)¹¹ is a commonly used general cognitive screening tool that assesses multiple domains and has broader application in stroke¹² than the Mini-Mental State Examination (MMSE).¹³ However, general screens like the MoCA and MMSE exhibit floor- and ceiling-effects, with many stroke survivors in the “intermediate” range, making it difficult to define reliable cut-offs for impairment.¹⁴ Additionally, these domain-general screens may not be suitable for stroke patients impacted by focal neurological impairments such as aphasia, visual loss, neglect, apraxia, alexia or agraphia, further contributing to a selection bias and attrition.¹⁵

There is a shift to the use of domain-specific cognitive screens such as the Oxford Cognitive Screen (OCS) which were designed to be more inclusive of stroke patients^15,16 and to account for stroke focal neurological deficits with aphasia- and neglect-friendly measures.⁶ However, even these assessments are limited by significant attrition, with roughly 50% attrition at 6-month follow-up.¹⁶

Unlike these cognitive screens, detailed in-person cognitive batteries¹⁷ can distil key components of full neuropsychological assessments into feasible assessments that capture multiple cognitive domains. While they provide more detailed cognitive characterization, these in-person 30–90-min batteries are not feasible for multi-center international clinical trials. They must be completed by a trained administrator and are time-consuming and costly.¹⁸

In-person testing of any sort exclude participants with difficulty attending clinics due to physical and cognitive limitations.¹⁸ This may lead to sampling biases, as those with greater cognitive impairment may be less able or less likely to return for in person assessments or to consent to detailed cognitive testing. Indeed, prior cognitive sub-studies of stroke trials (VITATOPS,¹⁹ ESCAPE,²⁰ SECRET²¹) with in-person cognitive assessments have shown frequent non-random missingness.

The use of cognitive assessments delivered remotely, by telephone or online, has potential to address some of the limitations presented by in-person assessments.²² Remote assessments increase convenience for participants, and avoid concerns of travel. Especially since the COVID pandemic, the potential for remote testing has received much more attention.²³ On an individual participant level, both telephone and online assessments show excellent correspondence to in-person pen-and-paper tasks,⁶ but the feasibility of implementing remote cognitive testing in the context of multi-center stroke clinical trials has not been previously characterized.

Objective

The objectives of this study were: (1) to investigate the feasibility of remote cognitive testing as a secondary endpoint in a multi-center randomized controlled trial in acute ischemic stroke and (2) to determine quantitative and qualitative factors that relate to remote cognitive test completion.

Methods

Patients

All patients were recruited from the Alteplase compared to Tenecteplase (AcT) clinical trial.²⁴ AcT randomized all participants with an acute ischemic stroke who met criteria for intravenous thrombolysis²⁵ from December 10, 2019 to January 25, 2022. The substudy was initiated after the main trial had begun, and not all sites were involved. To reduce sampling bias, all potential English-speaking consenting participants enrolled in the parent trial (treated with either intravenous alteplase or tenecteplase), who completed the parent trial’s primary outcome independently, and were within 90–180 days from randomization were eligible for this substudy. A single trained assessor (SS) contacted all potentially eligible participants. To minimize attrition, voicemail message were left at the primary contact number (used for main study primary outcome assessment), or alternative contacts where available. After maximum of five voicemail messages without response within the 180-day window, participants were considered lost to follow-up. Participants who could not complete cognitive testing, including those with severe aphasia (unable to talk on the phone) and those who were not fluent in English, were excluded. The substudy was approved by the research ethics board at all sites from which participants were recruited.

Cognitive assessment

Consenting participants completed the T-MoCA,²⁶ a modified version of the MoCA designed for remote/telephone administration.⁶ SS obtained certification from the official MoCA website (mocacognition.com) before assessing participants. After completing the T-MoCA, those able and willing completed an abbreviated Creyos battery.^18,27 We selected Creyos battery as a standardized, easy to access set of test that have a very large normative dataset,^27–29 and for which the subtest have been validated against pen-and-paper cognitive tasks.^30–32 The scores can be combined to form three key factor-based domain scores of interest – Reasoning Ability, Verbal Ability, and Short Term Memory.²⁷ Consenting participants received an individualized URL link via email to complete the online assessment. Over the phone, SS ensured the participant could access the assessment, understand how the tests worked and navigate the video instructions and online practice rounds before the participant completed the task independently. If the participants encountered any difficulties, SS was available by phone to provide prompt assistance. Participants without access to a computer or a stable internet connection (home, library, clinic) were not eligible for online testing. The cognitive tasks used for this study included: Paired Associates, Monkey Ladder, Rotations, Odd One Out, Digit Span, and Grammatical Reasoning (creyos.com).

Structured qualitative exit interviews

Structured qualitative exit interviews³³ were performed with all consenting participants after attempting the Creyos and were collected from July 2021 to July 2022. The interviews were conducted over the phone and analyzed by trained interviewers (SS & PP). The structured interview guides were designed for specific participant populations: (a) those that successfully completed all Creyos assessments, (b) those that began the online tasks but did not finish all Creyos assessments. The last group (c) who were eligible but did not undertake the Creyos assessments, were only asked a single, multiple select question exit survey (Supplemental Data, Section 2 (Methods – pages 4–5).

Statistical analysis

Proportion of participants completing telephone and computerize cognitive assessments are reported. Descriptive statistics, including mean and standard deviations, were calculated for continuous variables age, quality of life (EQ-VAS), length of hospital stay, onset to needle time (OTN), door to needle time (DTN), and assessed with t-test (Supplemental Table 1). Proportions were reported for categorical variables such as enrolling center type (primary or comprehensive stroke center), affected hemisphere and occlusion sites, and assessed with a chi-square test (Supplemental Table 1). Logistic regression models were used to examine the association between demographic and clinical variables and completion of remote cognitive testing (yes/no) with independent models for T-MoCA or Creyos completion. Models controlled for age, sex, 90 day follow-up modified Rankin Scale (mRS), treatment type, enrolling center type, registry (QuICR³⁴ vs OPTIMIZE,³⁵ are Canadian acute stroke registries that collected process of care metrics – QuICR in Alberta and OPTIMIZE in the rest of Canada), baseline National Institutes of Health Stroke Scale (NIHSS), length of hospital stay, process metrics (Onset-to-Needle (OTN)/Door-to-Needle (DTN)), self-rated quality of life (QoL) using EQ-VAS, presence of large vessel occlusion (LVO), affected hemisphere and occlusion site on computer tomography angiography (CTA), ethnicity, education and computer proficiency score.³⁶ All models were assessed for multicollinearity using variance inflation factor (VIF) with a cut-off < 5. Only complete observations were utilized in all models, with pairwise deletion. Associations between variables within the models were set at p < 0.05, two-sided test. Statistical analyses were performed using R-programing (version 4.2.3).

Structured qualitative interview analysis

Structured qualitative interview data were analyzed using a combination of standard thematic analysis technique³⁷ to identify themes and content analysis to quantify the frequency of themes related to computerized cognitive assessment. Research team members SS and PP independently reviewed the transcripts, identified sections that reflected the key domains of interest. Subthemes that expressed similar experiential patterns were brought together to develop core themes. The exit survey was analyzed exclusively using content analysis. Additional details are available in the Supplemental Data, Section 2 (Methods – pages 4–5).

Results

Completion of cognitive assessments

Amongst the 1577 patients in the intention to treat analysis of the AcT Trial,²⁴ 786 (49.8%) were not eligible for the cognitive sub-study (Figure 1). Of the remaining 791 potentially eligible patients for this cognitive sub-study (mean age 70 ± 14 years, and median mRS of 2), 409 (52%) were able to speak independently on the phone and agreed to answer questionnaires. They were all recruited within 180 days from randomization. Of those, 401 participants (51% of the 791 potentially eligible) consented and completed the T-MoCA. Of these 401 participants (mean age 66 ± 13 years), 156 (38.9%) participants were female and 207 (52%) were assigned to tenecteplase. About 242 participants (31% of the 791 potentially eligible; mean age 64 ± 12 years) consented and competed Creyos. Of these, 92 (38%) were female and 124 (51%) were assigned to tenecteplase (Supplemental Table 1). Common reasons for Creyos incompletion included 18.5% of participants needing assistance at home, lacking computer access, or having visual/motor impairments, and 20% of participants declining consent or not returning calls (Figure 1). In univariate analyses, compared to those not completing cognitive testing, participants who completed a T-MoCA or Creyos (Supplemental Table 1) were more likely to be younger, male, with lower baseline stroke severity (NIHSS), have better functional outcome at 90 days (mRS 0–1), have better self-rated QoL at 90-days and have had an earlier discharge from hospital.

Figure 1.

Patient flowchart from the parent Alteplase compared to Tenecteplase (AcT) trial into the cognitive sub-study (AcT-Cog), highlighting the exclusion/missingness.

Multivariate analysis of factors associated with T-MoCA and Creyos completion

For all models, occlusion location on CTA was removed as it had a VIF > 5. Table 1 describes the results of the two multivariable logistic regressions exploring the association of T-MoCA and Creyos completion (yes/no) respectively with demographic and clinical variables (n = 791). For T-MoCA, age (OR: 0.95 per age increase, 95% CI: 0.94–0.97), grouped mRS – 2–5 (OR: 0.55 compared to mRS 0–1, 95% CI: 0.37–0.81), EQ-VAS (OR: 1.02 per point increase, 95% CI: 1.01–1.03), and length of hospital stay (OR: 0.98 per 1-day increase, 95% CI: 0.96–0.99) were independently associated with completion. For Creyos, age (OR: 0.95 per age increase, 95% CI: 0.94–0.96), mRS 2–5 (OR: 0.66 compared to mRS 0–1, 95% CI: 0.44–0.98), EQ-VAS (OR: 1.02 per point increase, 95% CI: 1.01–1.03) and length of hospital stay (OR: 0.97 per 1-day increase, 95% CI: 0.94–0.99) were also independently associated with completion.

Table 1.

Predicting Telephone Montreal Cognitive Assessment (T-MoCA) and Creyos completion in potentially eligible Alteplase compared to Tenecteplase cognitive sub-study (AcT-Cog) participants (n = 791). Determining relationship of T-MoCA and Creyos completion with key demographic and clinical variables.

Term	Odds ratio of T-MoCA completion (95% confidence interval)	Odds ratio of Creyos completion (95% confidence interval)
Sex – Female	0.89 (0.63–1.25)	1.04 (0.73–1.50)
Age	0.95 (0.94–0.97)*	0.95 (0.94–0.96)*
Grouped Modified Rankin Scale – 2–5	0.55 (0.37–0.81)*	0.66 (0.44–0.98)*
Drug - tenecteplase	1.02 (0.73–1.42)	0.95 (0.67–1.35)
Type of Enrolling Center – comprehensive center	0.81 (0.46–1.41)	1.25 (0.70–2.25)
Source – QUICR	0.82 (0.59–1.15)	0.92 (0.65–1.31)
Large vessel occlusion on computed tomography angiography (CTA) – Yes	1.54 (0.93–2.53)	1.48 (0.87–2.51)
Onset-to-needle time (min)	1.00 (1.00–1.00)	1.00 (1.00–1.00)
Door-to-needle time (min)	1.00 (1.00–1.01)	1.00 (1.00–1.01)
EQ – Visual Analog Scale (VAS)	1.02 (1.01–1.03)*	1.02 (1.01–1.03)*
Length of hospital stay	0.98 (0.96–0.99)*	0.97 (0.94–0.99)*
Baseline NIHSS	0.97 (0.94–1.00)	0.97 (0.94–1.00)
Occlusion site on CTA (compared to patients with no visual occlusion on CTA)
Left	0.90 (0.58–1.39)	0.90 (0.57–1.44)
Right	1.31 (0.80–2.13)	0.98 (0.58–1.64)
Bilateral	2.30 (0.38–13.84)	1.87 (0.36–9.70)
Midline (Brainstem)	1.15 (0.3–4.37)	0.48 (0.12–1.92)

Significant results (p < 0.05) are bolded.

In both models (Table 1) increasing age, more severe functional impairment and longer hospital stays were correlated with lower likelihood of completing the T-MoCA and Creyos, while higher scores on EQ-VAS (better self-rated quality of life) correlated with increased T-MoCA and Creyos completion.

Supplemental Table 2 describes the multivariable logistic regression of the association between demographic and clinical variables and the likelihood of Creyos online cognitive assessment completion (yes/no) in the subset of people who were independently able to speak on the phone (n = 409). In this group, only computer proficiency (OR: 1.12 per point increase, 95% CI: 1.04–1.21) had a significant positive association with completion.

Structured qualitative interview and exit survey findings

There were two groups of interview participants: (a) those that successfully completed all Creyos assessments (n = 76); (b) those that attempted but did not finish Creyos (n = 3); and the last group (c) those who were eligible but who did not undertake the Creyos assessments, that only completed an exit survey (n = 43; Supplemental Table 3). A code book was developed using a thematic analysis of the Structured Qualitative Interview from groups (a) and (b) (Supplemental Table 4). The qualitative data showed that individuals who were able to complete Creyos preferred online testing due to improved accessibility and comfort. Without an administrator, participants felt they were limited in their opportunities to obtain feedback, had difficulty understanding task objectives and/or had reduced motivation to put forward their best efforts (Supplemental Table 4). Forty-five percent of the interviewed participants reported increased perceived difficulty in tasks (Supplemental Figure 1). Based on the brief exit survey, the most common self-reported reasons for declining participation on computerized testing were computer literacy challenges (49%), along with lack of interest (47%) and time demands of the tasks (44%; Supplemental Figure 2). Additional details regarding the results of the structured qualitative interview and exit survey is available in the Supplemental Data, Section 2 (Results – pages 6–12).

Discussion

Telephone screening or computerized cognitive assessments are not ideal as a secondary outcome for large acute stroke trials. In clinical trials, the prioritizing of primary outcome data can result in more variability in secondary endpoint data collection, particularly when these require additional participant engagement. In the parent AcT trial, data for the EQ-VAS quality of life at 90-days was missing for n = 74/1577 (5%)³⁸; however, this included both surrogate (patient/family) ratings, and imputation of lowest values for those who didn’t survive (n = 241). Thus, even during primary data collection, there can be significant missingness for variables that require direct participant response. For cognitive outcomes, especially requiring a second contact, even more participants declined to participate: whether via telephone (51%) or online (31%), completion rates were moderate and demonstrated survivor biases, with older and more severely affected participants less likely to complete assessments.

Remote cognitive testing has been proposed as an approach to help overcome some of the challenges introduced by in-person screens and gold standard testing including geographic barriers³⁹ and economic accessibility.⁴⁰ Our data show that any form of remote cognitive assessment can end up as a barrier to inclusivity and accessibility, with non-random missingness of data: older stroke survivors, those who experience worse quality of life, those with more severe strokes or with poor functional outcomes were less likely to complete our remote cognitive secondary outcomes. Since age and stroke severity are known correlates of cognitive function after stroke,⁴¹ the people with the greatest cognitive difficulties may also be the least likely to complete cognitive testing. It is likely that inability to complete cognitive testing is, in and of itself, a potential marker of poor post-stroke outcome as reflected by associations with poor functional outcome and quality of life.

The biases seen here do not only apply to hyperacute cohorts, or to remote cognitive testing. Indeed, the completion of remote detailed cognitive assessment reported here (30%) is similar to rates seen in a stable stroke prevention clinic sample⁴² where, out of 1400 patients attending stroke prevention clinics who underwent very brief screening, only 29% agreed to complete a 30 min in-person detailed cognitive assessment. In that sample, those that declined were also older, with greater stroke severity.⁴² Similarly, in the ESCAPE trial,²⁰ a 59% completion rate was reported for the in-person MoCA, comparable to our T-MoCA completion rate of 51%, with missing participants tending to be older and having severe stroke impairments. These studies suggest that biases introduced by cognitive testing after stroke is a problem for both acute and prevention trials and for both in-person and remote assessments. In contrast, the secondary prevention LACI-2⁴³ trial reported a completion rate of 85% for the T-MoCA. These trials, by nature of their inclusion criteria and prospective design, are by definition restricted to those willing and able to complete cognitive tests at baseline, which improves completion rates; yet, attrition still occurs non-randomly. More broadly, participants with Alzheimer’s disease⁴⁴ or heart failure⁴⁵ who do not complete follow-up cognitive testing are also more likely to be those with poor cognitive and/or functional outcomes. With significant reductions in sample sizes and non-random missingness, cognitive outcomes reported in randomized trials have a high risk of bias, limiting the translational aspect of trial findings.⁴⁶

In stroke clinical trials, measuring cognitive impairment requires direct participant assessment, so is necessarily limited to those who are able and willing to participate.

An alternative approach that identifies meaningful cognitive outcomes for all patients in acute stroke trials is required. One approach, used in the recently published LACI-2⁴³ randomized clinical trial, involved a 7-level ordinal cognitive outcome status⁴⁷ designed to reflect DSM-5 criteria for neurocognitive impairment. Each category was operationalized using a combination of T-MoCA and/or the modified Telephone Interview for Cognitive Status (TICS-m) scores,⁴⁷ plus mRS or Barthel functional measures. In this setting, 86% of people completed either a T-MoCA or TICS and a functional outcome and could thus generate an ordinal cognitive outcome. This scale has some limitations – for example, application for individuals with discrepant cognitive and functional status may be inconsistent, and data were still missing in 14% of participants. While the LACI-2 trial utilized validated cognitive screens (T-MoCA and TICS-m) and functional measures (mRS or Barthel), the novel ordinal scale operationalized using various cut-offs has not been validated against gold standard neuropsychological testing. However, it is nonetheless an important attempt to create an ordinal scale that reflects cognitive function and is available in majority of the participants. This represents a necessary progression away from reliance only on direct cognitive screening or standardized cognition as outcomes.

Other, indirect approaches to cognition, such as machine learning analysis of recorded spontaneous speech samples,⁴⁸ in person or video eye-tracking technology,⁴⁹ or a combination of both,⁵⁰ may help to account for participants too impaired for traditional cognitive tasks. Additionally, caregiver or family-reported concerns can provide insights into cognitive problems experienced by the patient.⁵¹ Indirect measures of cognition from informants include standardized participant or informant rating of cognitive function (e.g. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)⁵²) and cognitively focused instrumental activities of daily living (e.g. Lawton and Brody Instrumental Activities of Daily Living (IADL)⁵³). These validated questionnaires are relatively unaffected by social and cultural biases and can even be compared to a participants baseline to account for pre-stroke function and post-stroke cognitive changes.⁵⁴ Though these assessments do not provide a direct reflection of global cognition or specific cognitive domains, they identify functionally important changes attributable to cognitive impairment.

Cognitive impairments can significantly impact a person’s independence, quality of life and clinical outcomes.⁵⁵ However, there is limited literature on the ideal assessment method and the optimal duration for follow-up within stroke clinical trials.⁸ Our findings indicate that employing remote telephone or computerized cognitive assessment as a secondary endpoint in a large acute clinical trial is heavily influenced by attrition and survivor biases. Future stroke trials aiming to assess cognition should embed cognitive assessments within the primary endpoint visit whenever possible. Additionally, the use of informant-reported questionaries could help to limit missingness and obtain outcomes for all participants – regardless of age and stroke severity.

Limitations

This study examined a cohort of English-speaking participants enrolled in a time-sensitive acute stroke treatment trial, with cognition as a secondary endpoint. The completion rates reflect the outcomes of hyperacute stroke, with high rates of mortality and functional impairment affecting recruitment and attrition. Further, some potentially eligible patients were missed if they were enrolled in the trial at sites not participating in this substudy, or completed the trial before local ethics approval was obtained for the substudy. Predictor variables were necessarily limited to those available for all participants in the primary trial; hence, some variables, such as primary language spoken or socio-economic status, that were not collected in AcT could not be used in models predicting test completion. Participants had to speak to a coordinator by phone to access the online assessment, potentially limiting participation from those who would prefer to avoid phone calls and access computer testing directly. Additionally, the structured qualitative interviews and exit surveys were also necessarily limited to those who completed the telephone assessment. As with the cognitive testing, the language requirement of the qualitative questions may have limited participant comprehension. It is possible that other telephone or computer assessments may have had different completion rates; however, both the regression data and the qualitative interviews suggest that completion is more related to participant factors than test-specific factors. It is also important to note that while the Creyos online tests are based on validated pen-and-paper tasks, the online assessment themselves have not been directly validated in stroke, and do not cover all domains of stroke-specific cognition. As this substudy required a secondary contact, 1–3 months after the primary study endpoint assessment, it carried a higher risk for attrition.

Conclusion

To improve cognitive outcomes after stroke, it is essential to include cognitive measures (direct or indirect) as outcome events in clinical trials. Our results reinforce the need for clinical trials to identify more pragmatic cognitive outcome events, that can be collected as a primary or secondary outcome at time of primary assessment, and that can be facilitated or completed by surrogates for more severely affected participants. Further, studies of cognitive outcomes must transparently report rates of missingness, identify reasons for incompletion (declining consent for convenience or lack of time commitment vs lack of capacity) and account for non-random missingness by controlling for key variables identified here, including age, stroke severity, QoL and length of hospital stay.

Supplemental Material

sj-docx-1-eso-10.1177_23969873251323171 – Supplemental material for Feasibility of telephone and computerized cognitive testing as a secondary outcome in an acute stroke clinical trial: A mixed methods sub-study of the AcT Trial

Supplemental material, sj-docx-1-eso-10.1177_23969873251323171 for Feasibility of telephone and computerized cognitive testing as a secondary outcome in an acute stroke clinical trial: A mixed methods sub-study of the AcT Trial by Sajeevan Sujanthan, Pugaliya Puveendrakumaran, Katie N Dainty, Morgan Barense, Krista L Lanctot, Adrian M Owen, Nishita Singh, Brian H Buck, Houman Khosravani, Shelagh B Coutts, Mohammed Almekhlafi, Ramana Appireddy, Aleksander Tkach, Jennifer Mandzia, Heather Williams, Thalia S Field, Alejandro Manosalva, Muzaffar Siddiqui, Gary Hunter, MacKenzie Horn, Fouzi Bala, Michael D Hill, Michel Shamy, Aravind Ganesh, Tolulope Sajobi, Bijoy K Menon and Richard H Swartz in European Stroke Journal

Footnotes

Acknowledgements

We would like to acknowledge the AcT participants who volunteered their time for this study.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RHS reports ownership shares in FollowMD Inc., a virtual vascular risk reduction clinic, has participated in an advisory board for Roche and holds the Bastable-Potts Chair in Stroke Research at Sunnybrook HSC, University of Toronto. NS reports salary support from Heart & Stroke Foundation of Canada, Research Manitoba and University of Manitoba. None of the other authors have any conflicts of interest to disclose.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by CIHR (Grant Ref No. 462762).

Informed consent

Informed consent was obtained from all subjects during the initial AcT trial randomization, and a subsequent verbal informed consent was obtained before the cognitive sub-study.

Ethics approval

The substudy was approved by the research ethics board at all sites from which participants were recruited.

Trial registration

ClinicalTrials.gov, NCT03889249

Guarantor

RHS

Contributorship

All authors have reviewed and edited the manuscript and approved the final version of the manuscript. SS – Conceptualization, data collection, formal analysis, writing – original draft, reviewing and editing. PP – Data collection, formal analysis, writing – review and editing. KND – Resources, supervision, writing – review and editing. MB – Resources, supervision, writing – review and editing. KLL – Resources, supervision, writing – review and editing. AMO – Resources, supervision, writing – review and editing. NS – Resources, supervision, writing – review and editing. BHB – Resources, supervision, writing – review and editing. HK – Resources, supervision, writing – review and editing. SBC – Resources, supervision, writing – review and editing. MA – Resources, supervision, writing – review and editing. RA – Resources, supervision, writing – review and editing. AT – Resources, supervision, writing – review and editing. JM – Resources, supervision, writing – review and editing. HW – Resources, supervision, writing – review and editing. TSF – Resources, supervision, writing – review and editing. AM – Resources, supervision, writing – review and editing. MS – Resources, supervision, writing – review and editing. GH – Resources, supervision, writing – review and editing. MH – Resources, supervision, writing – review and editing. FB – Resources, supervision, writing – review and editing. MDH – Resources, supervision, writing – review and editing. AG – Resources, supervision, writing – review and editing. TS – Resources, supervision, writing – review and editing. BKM – Funding, conceptualization, resources, supervision, writing – reviewing and editing. RHS – Funding, conceptualization, resources, supervision, writing – original draft, reviewing and editing.

ORCID iDs

Sajeevan Sujanthan

Fouzi Bala

Michael D Hill

Richard H Swartz

Data availability

All data that support the findings of this study can be made available upon request.

Supplemental Material

Supplemental material for this article is available online.

References

Sun

Tan

JT.

Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med 2014; 2: 80.

Patnode

Perdue

Rossom

, et al. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA 2020; 323: 764–785.

Kwon

Lee

, et al. Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. J Neurol 2020; 267: 688–693.

Cramer

Wolf

Saver

, et al. The utility of domain-specific end points in acute stroke trials. Stroke 2021; 52: 1154–1161.

Kapoor

Lanctôt

Bayley

, et al. “Good outcome” isn’t good enough: cognitive impairment, depressive symptoms, and social restrictions in physically recovered stroke patients. Stroke 2017; 48: 1688–1690.

Quinn

Richard

Teuschl

, et al. European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment. Eur Stroke J 2021; 6: I–XXXVIII.

Lanctôt

Lindsay

Smith

, et al. Canadian stroke best practice recommendations: mood, cognition and fatigue following stroke, 6th edition update 2019. Int J Stroke 2020; 15: 668–688.

ElHusseini

Katzan

Rost

, et al. Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association. Stroke 2023; 54: E272–E291.

Lees

Fearon

Harrison

, et al. Cognitive and mood assessment in stroke research: Focused review of contemporary studies. Stroke 2012; 43: 1678–1680.

10.

Lees

Selvarajah

Fenton

, et al. Test accuracy of cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke. Stroke 2014; 45: 3008–3018.

11.

Nasreddine

Phillips

Bédirian

, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.

12.

Suda

Muraga

Ishiwata

, et al. Early cognitive assessment following acute stroke: feasibility and comparison between mini-mental state examination and Montreal Cognitive Assessment. J Stroke Cerebrovasc Dis 2020; 29: 104688.

13.

Folstein

McHugh

PR.

“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.

14.

Swartz

Cayley

Lanctôt

, et al. Validating a pragmatic approach to cognitive screening in stroke prevention clinics using the Montreal Cognitive Assessment. Stroke 2016; 47: 807–813.

15.

Demeyere

Riddoch

Slavkova

, et al. Domain-specific versus generalized cognitive screening in acute stroke. J Neurol 2016; 263: 306–315.

16.

Milosevich

Kusec

Pendlebury

, et al. Domain-specific cognitive impairments, mood and quality of life 6 months after stroke. Disabil Rehabil 2025; 47: 435–444.

17.

Hachinski

Iadecola

Petersen

, et al. National Institute of Neurological Disorders and Stroke–Canadian stroke network vascular cognitive impairment harmonization standards. Stroke 2006; 37: 2220–2241.

18.

Honarmand

Malik

Wild

, et al. Feasibility of a web-based neurocognitive battery for assessing cognitive function in critical illness survivors. PLoS One 2019; 14: e0215203.

19.

Hankey

Ford

, et al. Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. Stroke 2013; 44: 2232–2239.

20.

Joundi

Smith

Mandzia

, et al. Effect of endovascular thrombectomy for acute ischemic stroke on cognitive outcomes a secondary analysis of the ESCAPE trial. Neurology 2024; 102(10): e209270. DOI: 10.1212/WNL.0000000000209270

21.

Field

Dizonno

Almekhlafi

, et al. Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of-care in symptomatic cerebral venous thrombosis. Stroke 2023; 54: 2724–2736.

22.

Wild

Howieson

Webbe

, et al. The status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement 2008; 4: 428–437.

23.

Geddes

O’Connell

Fisk

, et al. Remote cognitive and behavioral assessment: report of the Alzheimer Society of Canada Task Force on dementia care best practices for COVID-19. Alzheimer Dement 2020; 12: e12111.

24.

Menon

Buck

Singh

, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022; 400: 161–169.

25.

Sajobi

Singh

Almekhlafi

, et al. Alteplase compared to tenecteplase in patients with acute ischemic stroke (AcT) trial: Protocol for a Pragmatic Registry linked randomized clinical trial. Stroke 2022; 11. DOI: 10.1161/SVIN.121.000447.

26.

Pendlebury

Welch

Cuthbertson

, et al. Telephone assessment of cognition after transient ischemic attack and stroke: modified telephone interview of cognitive status and telephone Montreal cognitive assessment versus face-to-face Montreal cognitive assessment and neuropsychological battery. Stroke 2013; 44(1): 227–229.

27.

Hampshire

Highfield

Parkin

, et al. Fractionating human intelligence. Neuron 2012; 76: 1225–1237.

28.

Owen

Hampshire

Grahn

, et al. Putting brain training to the test. Nature 2010; 465: 775–778.

29.

Wild

Nichols

Battista

, et al. Dissociable effects of self-reported daily sleep duration on high-level cognitive abilities. Sleep 2018; 41(12): zsy182. DOI: 10.1093/SLEEP/ZSY182.

30.

Thienel

Borne

Faucher

, et al. Can an online battery match in-person cognitive testing in providing information about age-related cortical morphology? Brain Imaging Behav 2024; 18(5): 1215–1225.

31.

Brenkel

Shulman

Hazan

, et al. Assessing capacity in the elderly: comparing the MoCA with a novel computerized battery of executive function. Dement Geriatr Cogn Dis Extra 2017; 7: 249–256.

32.

Sternin

Burns

Owen

AM.

Thirty-five years of computerized cognitive assessment of aging-where are we now?

Diagnostics 2019; 9: 114. DOI: 10.3390/DIAGNOSTICS9030114.

33.

Kvale

Brinkmaan

. (eds.). InterViews: learning the craft of qualitative research interviewing. 2nd ed. PsycNET. Sage Publications, Inc., Thousand Oaks, CA, 2009. https://psycnet.Apa.org/record/2008-15512-000 (accessed 15 December 2021).

34.

Kamal

Jeerakathil

Mrklas

, et al. Improving door-to-needle times in the treatment of acute ischemic stroke across a Canadian province: methodology. Crit Pathw Cardiol 2019; 18: 51–56.

35.

Katsanos

Poppe

Swartz

, et al. Interhospital transfer for endovascular stroke treatment in Canada: results from the OPTIMISE registry. Stroke 2024; 55: 2103–2112.

36.

Boot

Charness

Czaja

, et al. Computer proficiency questionnaire: assessing low and high computer proficient seniors. Gerontologist 2015; 55: 404–411.

37.

Braun

Clarke

Using thematic analysis in psychology. Qual Res Psychol 2006; 3: 77–101.

38.

Sajobi

Arimoro

Ademola

, et al. Quality of life after intravenous thrombolysis for acute ischemic stroke: results from the AcT randomized controlled trial. Stroke 2024; 55: 524–531.

39.

Owens

Ballard

Beigi

, et al. Implementing remote memory clinics to enhance clinical care during and after COVID-19. Front Psychiatry 2020; 11: 579934.

40.

Bardram

Remote assessment in healthcare—technologies, methods, benefits, and challenges. PLoS One 2023; 18: e0283945.

41.

Ferreira

MGR

Moro

CHC

Franco

. Cognitive performance after ischaemic stroke. Dement Neuropsychol 2015; 9: 165–175.

42.

Swartz

Cayley

Lanctôt

, et al. The “DOC” screen: feasible and valid screening for depression, obstructive sleep apnea (OSA) and cognitive impairment in stroke prevention clinics. PLoS One 2017; 12: e0174451.

43.

Wardlaw

Woodhouse

Mhlanga

, et al. Isosorbide mononitrate and cilostazol treatment in patients with symptomatic cerebral small vessel disease: the Lacunar Intervention Trial-2 (LACI-2) randomized clinical trial. JAMA Neurol 2023; 80: 682–692.

44.

Burke

Naseh

, et al. Factors influencing attrition in 35 Alzheimer’s disease centers across the USA: a longitudinal examination of the National Alzheimer’s coordinating center’s uniform data set. Aging Clin Exp Res 2019; 31: 1283–1297.

45.

Holm

Bachus

Jujic

, et al. Cognitive test results are associated with mortality and rehospitalization in heart failure: Swedish prospective cohort study. ESC Heart Fail 2020; 7: 2948–2955.

46.

Gencheva

Sloan

Leurgans

, et al. Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology 2004; 23: 61–66.

47.

Wardlaw

Doubal

Brown

, et al. Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: protocol introduction and rationale. Eur Stroke J 2021; 6: 89–101.

48.

García-Gutiérrez

Alegret

Marquié

, et al. Unveiling the sound of the cognitive status: machine learning-based speech analysis in the Alzheimer’s disease spectrum. Alzheimers Res Ther 2024; 16: 26–20.

49.

Oyama

Takeda

Ito

, et al. Novel method for rapid assessment of cognitive impairment using high-performance eye-tracking technology. Sci Rep 2019; 9: 12932–12939.

50.

Jang

Soroski

Rizzo

, et al. Classification of Alzheimer’s disease leveraging multi-task machine learning analysis of speech and eye-movement data. Front Hum Neurosci 2021; 15: 716670.

51.

McGovern

Pendlebury

Mishra

, et al. Test accuracy of informant-based cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke. Stroke 2016; 47: 329–335.

52.

Jorm

AF.

A short form of the informant questionnaire on cognitive decline in the elderly (IQCODE): development and cross-validation. Psychol Med 1994; 24: 145–153.

53.

Lawton

Brody

EM.

Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–186.

54.

Galvin

JE.

Using informant and performance screening methods to detect mild cognitive impairment and dementia. Curr Geriatr Rep 2018; 7: 19–25.

55.

Elendu

Amaechi

Elendu

, et al. Stroke and cognitive impairment: understanding the connection and managing symptoms. Ann Med Surg 2023; 85: 6057–6066.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB